Paul Richardson, MD, Dana-Farber Cancer Institute, Boston, MA, shares some results from a study evaluating the safety and efficacy of combining mezigdomide, a novel oral CELMoD, with dexamethasone and bortezomib or carfilzomib in patients with relapsed/refractory (R/R) multiple myeloma. Dr Richardson first provides some information on the mechanism of action of mezigdomide, and then goes on to discuss the response rates observed in this study. This interview took place at the 19th International Myeloma Society Meeting (IMS) held in Los Angeles, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
